AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

According to a new comprehensive report from The Insight Partners, the global ovarian cancer drugs market is observing ...

An AbbVie company and global leader in medical aesthetics, Allergan Aesthetics, has kicked off an intensive training programme for Nigerian doctors and aesthetic practitioners to raise safety ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

AbbVie’s stock danced a volatile jig on June 20th, teasing both bulls and bears before landing barely changed at $185.30. The ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Royalty Pharma will provide up to $1.25 billion in exchange for a synthetic royalty on annual worldwide net sales of daraxonrasib (and zoldonrasib if approved in an overlapping daraxonrasib indication ...